Summary
BeOne Medicines Ltd. (ONC), a biopharmaceutical company, announced a significant milestone on August 26, 2018, with the China Drug Administration (CDA) accepting its New Drug Application (NDA) for zanubrutinib. Zanubrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor being developed for patients suffering from relapsed/refractory mantle cell lymphoma (MCL). This acceptance by the CDA marks a crucial step in the drug development and commercialization process for BeOne Medicines, indicating that the regulatory authority will now review the application. Investors should monitor this development closely as it represents potential future revenue streams and a significant advancement in the company's pipeline, particularly in the oncology space.
Key Highlights
- 1China Drug Administration (CDA) accepted the New Drug Application (NDA) for zanubrutinib.
- 2Zanubrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor.
- 3The NDA is for the treatment of relapsed/refractory mantle cell lymphoma (MCL).
- 4This marks the first NDA acceptance for zanubrutinib by a major regulatory authority.
- 5The press release detailing this announcement was issued on August 26, 2018.
- 6The filing was made on August 27, 2018, as a Form 8-K.